- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care, as well as leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. The Department of Quantitative Clinical Pharmacology is the key provider of computer modelling analyses for efficacy and safety evaluation of drugs in development at Novo Nordisk. The main activities include: Population PK/PD modelling and simulation, biosimulation and clinical trial simulation.
The Department of Quantitative Clinical Pharmacology at Novo Nordisk will provide expertise in drug development and PK/PD-modelling in the area of diabetes. In addition, the departments strong experience with existing tools for modelling and simulation and previous participation in related standardisation activities will be used for the development of model description and markup languages.